Spravato treatment for Coral Springs — REMS-certified, insurance-covered TRD care.

RECO Integrated Psychiatry is a REMS-certified Spravato site 25 miles from Coral Springs — a 35-minute Sawgrass Expressway drive from Eagle Trace or Parkland Isles to the Delray Beach office. Every dosing session is run by the same psychiatry team managing the concurrent oral antidepressant, augmentation with aripiprazole or lithium, and TMS candidacy, so care is not fragmented across an infusion clinic and an outside prescriber. Benefits verification and prior authorization are completed before the first dosing visit, and per-session out-of-pocket cost is quoted in writing in advance.

Coral Springs sits 25 miles inland from RECO Integrated Psychiatry’s Delray Beach office — a 35-minute run down the Sawgrass Expressway to I-95 that puts Eagle Trace, Hidden Hammocks, and Parkland Isles inside a manageable morning window for the twice-weekly cadence Spravato induction requires. Esketamine is not a first-line antidepressant. It is an FDA-approved treatment for adults whose major depressive disorder has failed at least two prior antidepressant trials, and for major depressive disorder with acute suicidal ideation. RECO Integrated Psychiatry is a REMS-certified Spravato site delivered by the same psychiatry team that manages TMS, oral medication management, and telepsychiatry follow-up.

Spravato and the REMS protocol — what treatment actually looks like

Esketamine is a nasal spray, self-administered by the client under nursing supervision in a private treatment room. The FDA Risk Evaluation and Mitigation Strategy protocol governs every visit: identity verification, pre-dose blood pressure and heart rate, dispensing of the device from locked stock, and observation for two hours after the final spray. Blood pressure is rechecked at approximately 40 minutes, when transient systolic elevation is expected. Sedation is monitored continuously, and dissociative symptoms are assessed with the Clinician-Administered Dissociative States Scale (CADSS) at baseline and again at 40 minutes.

Clients cannot drive after a session. A ride home from Delray Beach is required for every dose. Food is limited for two hours before treatment to reduce nausea, and benzodiazepines are avoided within a few hours of dosing when clinically feasible because they can blunt the antidepressant signal. REMS registration, dispensing records, and post-monitoring documentation are handled by the office and submitted to the manufacturer registry on the client’s behalf.

Standard TRD dosing begins at 56 mg for session one and steps up to 84 mg for session two and thereafter, adjusted downward for tolerability if hypertension, sedation, or dissociative burden becomes limiting. Benefits are verified in advance so per-session out-of-pocket cost is quoted in writing before the first dosing visit.

The induction and maintenance schedule

For treatment-resistant major depressive disorder, induction runs twice weekly for four weeks — eight sessions — followed by four once-weekly sessions, then maintenance dosing every one to two weeks based on PHQ-9 trajectory and clinician judgment. For the acute suicidal ideation indication, the schedule is twice weekly for four weeks with a separate maintenance decision made in coordination with a longer-term oral antidepressant plan.

Most clients notice some change within the first one to two weeks — usually shifts in sleep, rumination, or reactivity before mood itself lifts. Sustained response consolidates through the full eight-session induction; pivotal trial response rates clustered around 50 to 70 percent when esketamine was paired with a newly initiated oral antidepressant. Non-response by session eight is a signal to reassess rather than to push blindly — the psychiatry team reviews PHQ-9 and GAD-7 trajectories, side-effect burden, and adherence before extending, tapering, or pivoting to TMS or a medication change.

Discontinuation is a taper, not an abrupt stop. Spacing sessions to every two weeks, then every three, before ending treatment reduces relapse risk and gives the oral antidepressant time to carry the maintenance role.

Spravato with an oral antidepressant, not instead of one

The FDA label for esketamine is specifically for use in conjunction with an oral antidepressant — the pivotal trials paired it with a newly initiated SSRI or SNRI, and the label reflects that. Clients arriving on a partial-response agent such as sertraline, escitalopram, venlafaxine, or duloxetine typically continue that medication through induction; the psychiatry team may optimize the dose or add an augmenting agent like aripiprazole, lithium, or quetiapine depending on the response pattern.

Clients who have failed multiple antidepressants without partial benefit may start or switch an oral agent at the same time as beginning Spravato. There is no requirement for a “perfect” oral regimen before starting — the two treatments run in parallel and are managed by the same prescriber. Ongoing medication management for anxiety, insomnia, ADHD, or bipolar-spectrum concerns continues alongside Spravato without a separate outside psychiatrist.

The Spravato treatment plan is documented as an integrated psychiatric plan of care rather than a standalone infusion visit — a distinction that matters for prior authorization and for continuity if TMS or a medication change becomes appropriate later.

Spravato versus IV ketamine — how the psychiatry team chooses

Spravato and IV ketamine share a common mechanism at the NMDA receptor, but they are not clinically interchangeable. Spravato is FDA-approved for TRD and MDD with acute suicidal ideation, covered by most commercial plans, and delivered on a fixed 56 mg or 84 mg schedule. IV ketamine is off-label for depression, almost always cash-pay, and dosed by weight — typically 0.5 mg/kg over 40 minutes — with room to titrate for partial response.

End-to-end session time is comparable in practice, but the mechanics differ. Spravato is a nasal spray tied to a REMS registry and a required oral antidepressant. IV ketamine is an infusion, does not require a paired antidepressant, and is not bound by the same two-hour observation window. For clients with commercial insurance and documented TRD, Spravato is almost always the first choice on cost grounds alone. For clients who have failed Spravato, need weight-based titration, or fall outside the FDA-labeled indications, IV ketamine is discussed as an alternative or sequential option. Both are reviewed at the consult rather than defaulting to one.

What to expect on your first visit from Coral Springs

The initial evaluation is a 60-to-90-minute psychiatric intake — diagnostic history, prior antidepressant trials with doses and durations, baseline PHQ-9 and GAD-7, and a review of medical conditions that affect Spravato eligibility including uncontrolled hypertension, aneurysmal vascular disease, and recent intracerebral hemorrhage. The psychiatrist walks through the REMS requirements and initiates prior authorization the same day when TRD criteria are documented — typically two prior adequate antidepressant trials of six weeks each at therapeutic doses.

First dosing is usually scheduled within one to two weeks of the intake, once authorization returns. Plan on roughly three hours for a dosing visit: check-in and pre-dose vitals, self-administration under nursing observation, and the two-hour post-dose monitoring window. Arrange a ride home before leaving Coral Springs — the office cannot dismiss a client to drive themselves.

Insurance and admissions from Coral Springs

Spravato is covered under most commercial plans for documented TRD, including Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS. The office runs benefits verification and prior authorization before the first dosing visit, so deductible, coinsurance, and any per-session copay are quoted in writing in advance. For plans that require step therapy, the psychiatry team documents each prior antidepressant trial — agent, dose, duration, and reason for discontinuation — to satisfy medical necessity.

Scheduling from Coral Springs is designed around the induction cadence. Morning slots minimize traffic on the return leg via I-95 and the Sawgrass, and the concurrent oral antidepressant follow-ups can run by telepsychiatry between dosing visits so the total in-office footprint stays tight.

Serving residents of: Eagle Trace, Hidden Hammocks, Parkland Isles, Cypress Run, Heron Bay.